| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Wenyu Ye, Shinji Fujikoshi, Naohiro Nakahara, Michihiro Takahashi, Haya Ascher-Svanum, Tetsuro Ohmor. Improved outcomes following a switch to olanzapine treatment from risperidone treatment in a 1-year naturalistic study of schizophrenia patients in Japan. Psychiatry and clinical neurosciences. vol 66. issue 4. 2012-09-27. PMID:22624736. |
improved outcomes following a switch to olanzapine treatment from risperidone treatment in a 1-year naturalistic study of schizophrenia patients in japan. |
2012-09-27 |
2023-08-12 |
Not clear |
| Wenyu Ye, Shinji Fujikoshi, Naohiro Nakahara, Michihiro Takahashi, Haya Ascher-Svanum, Tetsuro Ohmor. Improved outcomes following a switch to olanzapine treatment from risperidone treatment in a 1-year naturalistic study of schizophrenia patients in Japan. Psychiatry and clinical neurosciences. vol 66. issue 4. 2012-09-27. PMID:22624736. |
this study assessed clinical and functional outcomes following a switch from risperidone to olanzapine in a 1-year naturalistic study of schizophrenia patients in japan. |
2012-09-27 |
2023-08-12 |
Not clear |
| Tim Lambert, Brett Emmerson, Harry Hustig, Sophie Resseler, An Jacobs, Belinda Butche. Long acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR database. BMC psychiatry. vol 12. 2012-09-26. PMID:22448928. |
long acting risperidone in australian patients with chronic schizophrenia: 24-month data from the e-star database. |
2012-09-26 |
2023-08-12 |
Not clear |
| Y-J Liou, Y M Bai, E Lin, J-Y Chen, T-T Chen, C-J Hong, S-J Tsa. Gene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics. The pharmacogenomics journal. vol 12. issue 1. 2012-09-24. PMID:20877301. |
the study included 456 schizophrenia patients treated with clozapine (n=171), olanzapine (n=91) and risperidone (n=194), for an average of 45.5±27.6 months. |
2012-09-24 |
2023-08-12 |
human |
| Dhanya Raveendranathan, Venkataram Shivakumar, Naveen Jayaram, Naren P Rao, Ganesan Venkatasubramania. Beneficial effects of add-on raloxifene in schizophrenia. Archives of women's mental health. vol 15. issue 2. 2012-09-24. PMID:22290018. |
we report the use of raloxifene as an adjunctive treatment, with risperidone, in treatment-resistant form of schizophrenia. |
2012-09-24 |
2023-08-12 |
Not clear |
| Ting-Sheng Chung, For-Wey Lun. Different impacts of aquaporin 4 and MAOA allele variation among olanzapine, risperidone, and paliperidone in schizophrenia. Journal of clinical psychopharmacology. vol 32. issue 3. 2012-09-19. PMID:22544010. |
different impacts of aquaporin 4 and maoa allele variation among olanzapine, risperidone, and paliperidone in schizophrenia. |
2012-09-19 |
2023-08-12 |
Not clear |
| Yoshihiro Tadori, Tetsuro Kikuch. [Pharmacology of antipsychotics at human dopamine D2 and D3 receptors]. Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology. vol 32. issue 1. 2012-09-13. PMID:22568121. |
antipsychotics (risperidone, olanzapine, amisulpride, sulpiride and perphenazine) which displayed antidepressive effects in schizophrenia patients behaved as preferential antagonists in cells expressing d2 receptors compared to cells expressing d3 receptors. |
2012-09-13 |
2023-08-12 |
human |
| Christian Asseburg, Michael Willis, Mickael Löthgren, Niko Seppälä, Mika Hakala, Ulf Persso. Hospitalisation Utilisation and Costs in Schizophrenia Patients in Finland before and after Initiation of Risperidone Long-Acting Injection. Schizophrenia research and treatment. vol 2012. 2012-09-12. PMID:22966445. |
hospitalisation utilisation and costs in schizophrenia patients in finland before and after initiation of risperidone long-acting injection. |
2012-09-12 |
2023-08-12 |
Not clear |
| Manfred Ackenheil, Klaus Webe. Developments in antipsychotic therapy with regard to hypotheses for schizophrenia. Dialogues in clinical neuroscience. vol 4. issue 4. 2012-09-10. PMID:22034064. |
abnormalities of the immune system in schizophrenia are being increasingly discussed: shifts in the levels of t helper cells subsets 1 and 2 (th1 and th2) have been observed, and studies with risperidone and the cyclooxengenase (cox2) inhibitor celecoxib as an add-on therapy have provided very promising results. |
2012-09-10 |
2023-08-12 |
Not clear |
| Philip R Szeszko, Katherine L Narr, Owen R Phillips, Joanne McCormack, Serge Sevy, Handan Gunduz-Bruce, John M Kane, Robert M Bilder, Delbert G Robinso. Magnetic resonance imaging predictors of treatment response in first-episode schizophrenia. Schizophrenia bulletin. vol 38. issue 3. 2012-08-30. PMID:21084552. |
structural mr imaging scans were acquired in 39 patients experiencing a first-episode of schizophrenia with minimal or no prior exposure to antipsychotics participating in a double-blind 16-week clinical trial comparing the efficacy of risperidone vs olanzapine. |
2012-08-30 |
2023-08-12 |
human |
| Paul G Barnett, Jennifer Y Scott, John H Krystal, Robert A Rosenhec. Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia. The Journal of clinical psychiatry. vol 73. issue 5. 2012-08-29. PMID:22697193. |
cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia. |
2012-08-29 |
2023-08-12 |
Not clear |
| Jean-Louis Goëb, Sophie Marco, Alain Duhamel, Renaud Jardri, Geraldine Kechid, Régis Bordet, Pierre Delion, Pierre Thoma. Metabolic side effects of risperidone in children and adolescents with early-onset schizophrenia. Primary care companion to the Journal of clinical psychiatry. vol 10. issue 6. 2012-08-23. PMID:19287568. |
metabolic side effects of risperidone in children and adolescents with early-onset schizophrenia. |
2012-08-23 |
2023-08-12 |
Not clear |
| Greg T Mah, Jane Dumontet, Anisha Lakhani, Susan Corriga. Evaluating appropriateness of prescribing of long-acting risperidone for injection in acute care settings. The Canadian journal of hospital pharmacy. vol 63. issue 6. 2012-08-23. PMID:22479015. |
long-acting risperidone for injection is a second-generation antipsychotic indicated for the treatment of schizophrenia and related psychotic disorders. |
2012-08-23 |
2023-08-12 |
Not clear |
| Wenyu Ye, Haya Ascher-Svanum, Yuka Tanji, Jennifer A Flynn, Michihiro Takahashi, Robert R Conle. Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis. Neuropsychiatric disease and treatment. vol 8. 2012-08-23. PMID:22745559. |
antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in japan: a health care database analysis. |
2012-08-23 |
2023-08-12 |
Not clear |
| Wenyu Ye, Haya Ascher-Svanum, Yuka Tanji, Jennifer A Flynn, Michihiro Takahashi, Robert R Conle. Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis. Neuropsychiatric disease and treatment. vol 8. 2012-08-23. PMID:22745559. |
this study compared the rate and the duration of antipsychotic monotherapy following initiation of olanzapine or risperidone in the treatment of outpatients with schizophrenia in japan. |
2012-08-23 |
2023-08-12 |
Not clear |
| Marise Machielsen, Albertine Scheltema Beduin, Nienke Dekker, René S Kahn, Don H Linszen, Jim van Os, Durk Wiersma, Richard Bruggeman, Wiepke Cahn, Lieuwe de Haan, Lydia Krabbendam, Inez Myin-Germey. Differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine. Journal of psychopharmacology (Oxford, England). vol 26. issue 1. 2012-08-21. PMID:21768161. |
differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine. |
2012-08-21 |
2023-08-12 |
human |
| Jin-Hua Wu, Hong Zou, Jun Yu, Xue-Dong Zhou, Qing-Lian Xie, Mei-Lei Ji. [Animal models of schizophrenia using different laboratory mouse strains]. Sheng li xue bao : [Acta physiologica Sinica]. vol 55. issue 4. 2012-08-16. PMID:12937815. |
risperidone, an atypical antipsychotic drug for treating schizophrenia in human, was used in the schizophrenia models using balb/c and c57bl/6 mice. |
2012-08-16 |
2023-08-12 |
mouse |
| Leslie Citrome, Josephine Cucchiaro, Kaushik Sarma, Debra Phillips, Robert Silva, Satoru Tsuchiya, Antony Loebe. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. International clinical psychopharmacology. vol 27. issue 3. 2012-07-24. PMID:22395527. |
clinically stable adult outpatients with schizophrenia were randomized in a 2 : 1 ratio to 12 months of double-blind treatment with once-daily, flexibly-dosed lurasidone (40-120 mg) or risperidone (2-6 mg). |
2012-07-24 |
2023-08-12 |
Not clear |
| b' Richard Barte\\xc4\\x8dek, Jan Ju\\xc5\\x99ica, Jana Zr\\xc5\\xafstov\\xc3\\xa1, Tom\\xc3\\xa1\\xc5\\xa1 Ka\\xc5\\xa1p\\xc3\\xa1rek, Eva Pindurov\\xc3\\xa1, Alexandra \\xc5\\xbdourkov\\xc3\\xa. Relevance of CYP2D6 variability in first-episode schizophrenia patients treated with risperidone. Neuro endocrinology letters. vol 33. issue 2. 2012-07-24. PMID:22592207.' |
relevance of cyp2d6 variability in first-episode schizophrenia patients treated with risperidone. |
2012-07-24 |
2023-08-12 |
Not clear |
| L Annemans, I Eijgelshoven, A Smet, A Jacobs, G Bergma. The impact of treatment with risperidone long-acting injection on the Belgian healthcare system: results from a budget impact model. Acta clinica Belgica. vol 67. issue 2. 2012-07-24. PMID:22712166. |
substantial evidence from randomised clinical trials has demonstrated that long-acting risperidone (rlai) is efficacious and well tolerated in patients with schizophrenia. |
2012-07-24 |
2023-08-12 |
Not clear |